1. Home
  2. ANTX vs FEMY Comparison

ANTX vs FEMY Comparison

Compare ANTX & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

31.2M

Sector

Health Care

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.55

Market Cap

37.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTX
FEMY
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.2M
37.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ANTX
FEMY
Price
$1.16
$0.55
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.00
$6.83
AVG Volume (30 Days)
137.4K
1.0M
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,061,502.00
Revenue This Year
N/A
$64.02
Revenue Next Year
N/A
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.53
52 Week Low
$1.00
$0.31
52 Week High
$1.55
$1.80

Technical Indicators

Market Signals
Indicator
ANTX
FEMY
Relative Strength Index (RSI) 48.13 36.54
Support Level $1.15 $0.57
Resistance Level $1.28 $0.73
Average True Range (ATR) 0.08 0.05
MACD -0.01 -0.00
Stochastic Oscillator 13.71 11.84

Price Performance

Historical Comparison
ANTX
FEMY

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: